Autres langues BLS Pharmaceuticals Limited

Actions

BLS

AU0000477796

Recherche biotechnologique et médicale

Marché Fermé - Australian S.E. 08:10:24 02/10/2026			Varia. 5j.	Varia. 1 janv.
1,020 ^AUD	0,00%		-0,97%	+142,86%

14/09	BLS Pharmaceuticals Limited annonce la nomination d'Angus Walker en tant qu'administrateur suppléant d'Edward Myer, avec effet au 14 septembre 2026	CI
02/09	Transcript : BLS Pharmaceuticals Limited, 2026 Earnings Call, Sep 02, 2026

Autres langues

21/09	BLS Pharmaceuticals Limited(ASX:BLS) added to S&P/ASX All Ordinaries Index
14/09	BLS Pharmaceuticals Limited Announces Appointment of Angus Walker as Alternate Director to Edward Myer, Effective September 14, 2026
31/08	BLS Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2027
31/08	BLS Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2026
27/07	BLS Pharmaceuticals Reports Record Revenue in June Quarter; Fiscal 2026 Revenue Hits Top End of Guidance Range
03/06	Bioxyne Limited Announces Appointment of Edward Myer as Independent Non-Executive Director and Independent Chair of Audit and Finance Committee
12/05	Bioxyne secures a$50m exclusive German supply agreement with Adrex
12/05	Bioxyne Unit Signs AU$50 Million Medicinal Cannabis Supply Deal With ADREXpharma
11/05	Bioxyne expands latam footprint first supply agreement Costa Rica
11/05	Bioxyne Unit Expands Supply Deal With Pharmaceutical Distributor; Shares Up 4%
21/04	Bioxyne Reports 137% Jump in Fiscal Q3 Revenue; Shares Fall 3%
01/04	Bioxyne Strikes Manufacturing Agreement With Aurora Cannabis; Shares Hit Eight-Year High
01/04	Bioxyne Limited Provides Update on Manufacturing Agreement with Aurora Cannabis Inc
31/03	Bioxyne signs manufacturing agreement with global cannabis leader, Aurora Cannabis
25/02	Bioxyne Limited Reaffirms Earnings Guidance for the Fiscal Year 2026
25/02	BLS Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2025
11/02	Bioxyne Secures Initial Purchase Orders for Psychedelic Drug; Shares Rise 7%
11/02	Bioxyne commercialises GMP-manufactured psilocybin capsules
28/01	Bioxyne reports quarterly revenue A$17.2 mln
11/12	Bioxyne Enters Costa Rica, Panama Medicinal Cannabis Markets with Manufacturing, Supply Agreement with Remidose; Shares Rise 3%
11/12	Bioxyne's unit enters manufacturing agreement with Remidose Latam Srl
02/12	Bioxyne Names Chief Financial Officer of Unit, Shares Fall 5%
26/11	Bioxyne Unit Ships Second GMP MDMA Batch to Victoria
17/11	Bioxyne's Unit Receives AU$1.7 Million Funding for UK Medical Cannabis Facility; Shares Fall 5%
11/11	Bioxyne Unit Fulfills Two Purchase Orders for MDMA Capsules in Australia